Tetanus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

June 2022 | 93 pages | ID: TB8A394B66ACEN
Global Markets Direct

Abstracts

Tetanus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tetanus – Drugs In Development, 2022, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.

Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tetanus – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 7, 6, 8, 2, 14, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Tetanus – Overview
Tetanus – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tetanus – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tetanus – Companies Involved in Therapeutics Development
Tetanus – Drug Profiles
Tetanus – Dormant Projects
Tetanus – Discontinued Products
Tetanus – Product Development Milestones
Featured News & Press Releases
Apr 26, 2022: KM Biologics files DTaP-IPV-Hib vaccine in Japan
Apr 12, 2022: Pertussis, Diphtheria, Tetanus, Polio, Hib vaccine filed in Japan: BIKEN/Mitsubishi
Apr 11, 2022: Marketing authorization application of pertussis, diphtheria, tetanus, inactivated polio and Hib combined vaccine (BK1310/MT-2355)
Mar 11, 2019: LG Chem gets $33.4 mil. from Gates Foundation for vaccine development
Aug 02, 2016: CanSino submits a clinical trial application for the component DTP diptheria tetanus pertussis combo vaccine (adults, teenagers and children above 6 years Old)
Sep 01, 2015: Commercialisation of a world changing invention for the stabilisation and delivery of vaccines
Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Tetanus, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Tetanus – Pipeline by AIM Vaccine Co Ltd, 2022
Tetanus – Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
Tetanus – Pipeline by Beijing Tiantan Biological Products Co Ltd, 2022
Tetanus – Pipeline by Biken Co Ltd, 2022
Tetanus – Pipeline by Biological E Ltd, 2022
Tetanus – Pipeline by BioNet-Asia Co Ltd, 2022
Tetanus – Pipeline by Boryung Pharmaceutical Co Ltd, 2022
Tetanus – Pipeline by CanSino Biologics Inc, 2022
Tetanus – Pipeline by Changchun Bcht Biotechnology Co Ltd, 2022
Tetanus – Pipeline by Chengdu Kanghua Biological Products Co Ltd, 2022
Tetanus – Pipeline by Chengdu Olymvax Biopharmaceuticals Inc, 2022
Tetanus – Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Tetanus – Pipeline by GC Biopharma Corp, 2022
Tetanus – Pipeline by KM Biologics Co Ltd, 2022
Tetanus – Pipeline by LG Chem Ltd, 2022
Tetanus – Pipeline by Novo Medi Sciences Pvt Ltd, 2022
Tetanus – Pipeline by NTxBio LLC, 2022
Tetanus – Pipeline by Panacea Biotec Ltd, 2022
Tetanus – Pipeline by Sanofi, 2022
Tetanus – Pipeline by Seasons Healthcare Ltd, 2022
Tetanus – Pipeline by Serum Institute of India Pvt Ltd, 2022
Tetanus – Pipeline by Shantha Biotechnics Pvt Ltd, 2022
Tetanus – Pipeline by Sichuan ZehaTimes Pharmaceutical Co Ltd, 2022
Tetanus – Pipeline by Stablepharma Ltd, 2022
Tetanus – Pipeline by Suzhou Weichao Biotechnology Co Ltd, 2022
Tetanus – Pipeline by VaxForm LLC, 2022
Tetanus – Pipeline by Yunnan Watson Biotechnology Co Ltd, 2022
Tetanus – Pipeline by Yuxi Jiuzhou Biological Technology Co Ltd, 2022
Tetanus – Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2022
Tetanus – Pipeline by Zydus Lifesciences Ltd, 2022
Tetanus – Dormant Projects, 2022
Tetanus – Dormant Projects, 2022 (Contd..1)
Tetanus – Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Tetanus, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022